Clinical Trials Logo

End Stage Liver Disease clinical trials

View clinical trials related to End Stage Liver Disease.

Filter by:
  • Active, not recruiting  
  • Page 1 ·  Next »

NCT ID: NCT05434286 Active, not recruiting - Cirrhosis, Liver Clinical Trials

Point-of-Care Echocardiography to Assess Impact of Dynamic Cardiac Function, Renal and Cardiac Biomarkers in Cirrhosis With Hepatorenal Syndrome-Acute Kidney Injury

Start date: December 15, 2021
Phase:
Study type: Observational

Point-of-care echocardiography (POC-Echo) is used to determine left ventricular systolic and diastolic dysfunction (LVDD), inferior vena cava (IVC) dynamics and volume status in cirrhosis and Acute-on-chronic liver failure ACLF accurately. We will assess IVC dynamics, LV systolic function [LV ejection fraction (EF) & cardiac output (CO)], and diastolic dysfunction (E/e', e' and E/A ratio) and urinary biomarkers (cystatin C and NGAL) in patients with cirrhosis and ACLF with hepatorenal syndrome-acute kidney injury (HRS-AKI).

NCT ID: NCT05195125 Active, not recruiting - Obesity Clinical Trials

Use of Direct Peritoneal Resuscitation in High-risk Liver Transplant Recipients

Start date: February 1, 2022
Phase: Phase 1
Study type: Interventional

This study is being conducted to assess the safety of Direct Peritoneal Resuscitation (DPR) in high-risk liver transplant patients. The investigators want to also identify if this method of recovery after large surgery has the same benefits in liver transplant patients as have been appreciated in other surgical patients. The combination of elevated BMI and impaired kidney function increases the risk of 1) needing intensive care unit (ICU) admission after surgery, 2) slow function of the new liver [technically termed Early Allograft Dysfunction (EAD)] and 3) need for more than one operation. The study team also aims to identify if DPR can reduce these risks and not cause other unexpected complications following surgery. DPR involves the infusion of a solution into the abdomen and has been shown to reduce edema and improve blood flow in organs. The solution used in this study is a commercially available peritoneal dialysate, a dextrose containing solution that is infused into the abdominal cavity and is routinely used in patients with end-stage renal disease requiring dialysis.

NCT ID: NCT04220723 Active, not recruiting - Clinical trials for End Stage Liver Disease

Evaluation of Frailty and Functional Capacity in End-Stage Liver Disease

Start date: November 20, 2022
Phase:
Study type: Observational

Development of fibrosis plays a main role in the pathophysiology of liver diseases. The rate of progression in fibrogenesis varies according to the type of underlying liver disease and varies with the environment and host-related factors. End-stage liver diseases are characterized by systemic vascular resistance and decreased arterial blood pressure, increased heart rate and cardiac output . Disruption of regulation of neurogenic, humoral and vascular functions is effective in these cardiovascular changes. In end-stage liver diseases, glycogen storage and corruption of glyconeogenesis cause muscle protein and fat to be used for energy, resulting in weight loss and muscle weakness. According to the latest data of the Republic of Turkey Ministry of Health in Turkey in 2223 patients are waiting for liver transplantation. Acute and chronic liver disease and infectious complications lead to an increase in the number of hospitalizations and prolonged hospital stay and severely affect the functional status and mortality. In recent years, more attention has been paid to complications from chronic diseases, including malnutrition, sarcopenia, poor functional capacity, and frailty. There are few studies in the literature examining functional capacity and physical frailty in end-stage liver disease. The aim of this study was to investigate the relationship between functional capacity and frailty in end-stage liver disease.

NCT ID: NCT03580629 Active, not recruiting - Clinical trials for End Stage Liver Disease

Pilot Study of the Liver Live Donor Champion Program

LLDC
Start date: September 18, 2018
Phase: N/A
Study type: Interventional

In this pilot study, investigators plan to enroll liver transplant candidates and a "Live Donor Champion" for an abridged two- or three-month program that provides education and advocacy training in order to expand access to live donor liver transplantation. Investigators have created two versions of the same program and based on feedback from participants and staff, investigators aim to analyze the efficacy of the Liver Liver Donor Champion program on this patient population.

NCT ID: NCT03089840 Active, not recruiting - Liver Diseases Clinical Trials

Normothermic Liver Preservation Trial

Start date: February 24, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This trial is to assess the safety and efficacy of normothermic machine perfusion (NMP) as an organ preservation method prior to transplantation using the OrganOx metraâ„¢ device.

NCT ID: NCT02889094 Active, not recruiting - HIV Clinical Trials

French HIV-HBV Cohort

COVViB
Start date: October 2016
Phase:
Study type: Observational

The overarching purpose of this study is to further understand the reasons for and clinical implications of persistent HBV infection in patients co-infected with HIV and HBV in the era of highly effective antiviral treatment against both viruses.

NCT ID: NCT01907074 Active, not recruiting - Clinical trials for End Stage Liver Disease

Quantitative Liver Function Tests Using Cholates

Start date: July 2011
Phase: Phase 2
Study type: Interventional

As the treatments for liver disease and the availability of liver transplantation have progressed, the number of patients with end stage liver disease continues to increase. This has increased the need to risk-stratify patients with cirrhosis to better direct their treatments and provide an accurate prognosis for their outcomes. The traditional assessment of the liver patient has been limited to imaging, static measures of "liver function tests" and liver biopsy. This protocol is designed to increase the spectrum of tests in the evaluation of the patient with end stage liver disease.

NCT ID: NCT01729221 Active, not recruiting - Clinical trials for Hepatocellular Carcinoma in Hepatitis C Virus Infected Patients

Application of the Stem Cell Therapy in the End Stage Liver Disease and Assessment Its Consequences in the Quality of Live Style as Well as Development of HCC.

Start date: January 2010
Phase: N/A
Study type: Observational

Prospective study to calculated the incidence of hepatocellular carcinoma in hepatitis C virus infected patients after stem cell therapy.

NCT ID: NCT01171742 Active, not recruiting - Clinical trials for End Stage Liver Disease

Effect of Intermittent Hepatic Inflow Occlusion During Donor Hepatectomy In Living Donor Liver Transplantation

Start date: July 2008
Phase: Phase 3
Study type: Interventional

Intermittent hepatic inflow occlusion (IHIO), also called Pringle maneuver, is a safe and effective procedure for major hepatectomy in patients with liver disease. In addition, ischemic preconditioning with IHIO has been reported to have protective effects in patients undergoing liver resection. The role of IHIO, however, has not been fully elucidated in donors and recipients during living donor liver transplantation.

NCT ID: NCT00163657 Active, not recruiting - Clinical trials for Liver Transplantation

Study of Liver Transplant For End-Stage Liver Disease Caused By Chronic Hepatitis C Infection

Start date: July 2002
Phase: Phase 4
Study type: Interventional

The purpose of this study is to compare three treatment regimens in patients who have received a liver transplant for end-stage liver disease caused by Chronic Hepatitis C infection.